Sat, Feb 28, 2015, 1:06 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Generex Biotechnology Corp. Message Board

  • biotechap biotechap Jan 14, 2013 12:29 PM Flag

    (NRIFF) Price: 0.065 // 3 Approved drugs + FDA decision on March 4 = 500%++ Potential


    You can buy this undiscovered Goldmine currently at almost all time low .GLTA

    FDA approval for the "Best in Class topical medication" on March 4 ,2013 . Nuvo has already a great Partnership with Big Player Covidien in place .

    Nuvo will hit profitability this year with 2 new product launches in 2Q 2013 .

    Upcoming Milestones 2013 :

    March 4, 2013 PDUFA date for Pennsaid 2%

    Q2 2013 worldwide launch of Pliaglis by Galderma


    Nuvo Research (NRI.TO) or (NRIFF)

    Market Cap : $ 36 M
    Cash: $ 12 M
    Price 0.065 $

     Growing revenue with 3 approved pain products:

     Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for
    U.S., targeting $8B oral NSAID market

     Pliaglis®: analgesic peelable cream, targeting global cosmetic and
    dermatology markets, partnered with Galderma, worldwide launch
    commencing Q2 2013


    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.018+0.001(+4.65%)Feb 27 3:57 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.